



Asthma Medication Ratio (AMR)

2024 Performance Year

Commercial and Medicaid

Measure Description

Percentage of patients ages 5–64 who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the performance year

Required Exclusions

- Patients in hospice or using a hospice benefit anytime during the performance year
- Patients who passed away anytime during the performance year
- Patients who weren't dispensed an asthma controller or reliever medication during the performance year
- Exclude patients with any of the following conditions during the patient's history through the end of the performance year:
 - Acute respiratory failure
 - Chronic obstructive pulmonary disease (COPD)
 - Chronic respiratory conditions due to fumes/vapors
 - Cystic fibrosis
 - Emphysema
 - Obstructive chronic bronchitis

Important Measure Notes

- Simplify treatment regimen, when possible.
- Use clear and simple language when providing directions on how to use inhalers.
- Help patients learn to identify and avoid asthma triggers.
- Educate patients on the difference between controller and reliever medications and applicable usage.
- Reminder: Dyphylline Guaifenesin Medications Lists have been removed

Medication Charts

To comply with this measure, a member must have the appropriate ratio of controller medications to total asthma medications



Asthma Controller Medications

Drug Category	Medications
Antibody inhibitors	Omalizumab
Anti-interleukin-4	Dupilumab
Anti-interleukin-5	Benralizumab, Mepolizumab, Reslizumab
Inhaled corticosteroids	Beclomethasone, Budesonid , Ciclesonide, Flunisolide, Fluticasone, Mometasone
Inhaled steroid combinations	Budesonide-formoterol, Fluticasone-salmeterol, Fluticasone-vilanterol, Formoterol-mometasone
Leukotriene modifiers	Montelukast, Zafirlukast, Zileuton
Methylxanthines	Theophylline

Asthma Reliever Medications

Drug Category	Medications
Short-acting, inhaled beta-2 agonists	Albuterol, Levalbuterol

Resources

HEDIS MY2024 Technical Specs Vol 2. Pg. 124-130